{"gene":"CSNK1G3","run_date":"2026-06-09T22:57:19","timeline":{"discoveries":[{"year":2006,"finding":"siRNA knockdown of CSNK1G3 significantly enhanced cancer cell killing in the presence of Akt inhibitor A-443654 and caused decreases in Akt Ser-473 and ribosomal protein S6 phosphorylation, identifying CSNK1G3 as an Akt-cooperating kinase required for Akt pathway activity in cancer cells.","method":"siRNA screen (kinome-wide RNAi library) with cell viability and phosphorylation readouts (Akt Ser-473, S6 phosphorylation)","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — functional siRNA knockdown with defined molecular readouts (phosphorylation), single lab, single method","pmids":["16247451"],"is_preprint":false},{"year":2018,"finding":"siRNA knockdown of CSNK1G3 negatively regulated aminoglycoside-mediated translation readthrough, indicating that CSNK1G3 kinase activity promotes readthrough at stop codons in competition with translation termination.","method":"siRNA knockdown in dual reporter-based high-throughput readthrough assay (enzymatic and fluorescence activities)","journal":"Human molecular genetics","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single siRNA knockdown assay, single lab, no direct mechanistic follow-up on how CSNK1G3 mediates the effect","pmids":["29177465"],"is_preprint":false},{"year":2024,"finding":"The curcumin derivative N17 inhibits p-AKT(S473) by specifically targeting CSNK1G3 protein, and CSNK1G3 was shown to regulate the AKT signaling axis controlling apoptosis and epithelial-mesenchymal transition in triple-negative breast cancer cells.","method":"Small-molecule targeting of CSNK1G3 with cell proliferation, apoptosis, and phosphorylation assays (p-AKT Ser473); EMT marker analysis","journal":"Biochemical pharmacology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, pharmacological inhibitor study without direct enzymatic reconstitution or structural validation; mechanism inferred from inhibitor effect","pmids":["39127154"],"is_preprint":false},{"year":2025,"finding":"A novel CSNK1G3-ALK gene fusion was identified in a lung squamous cell carcinoma patient, functioning as an oncogenic driver responsive to ALK tyrosine kinase inhibitors (alectinib, crizotinib, lorlatinib) in both the patient and a patient-derived xenograft model.","method":"DNA-based next-generation sequencing (NGS) identifying fusion; patient-derived xenograft (PDX) model treated with ALK-TKIs with tumor shrinkage readout","journal":"Clinical lung cancer","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single case/PDX model, no direct biochemical characterization of the fusion protein's kinase activity or mechanism","pmids":["40783309"],"is_preprint":false},{"year":2025,"finding":"circRNA-Csnk1g3 directly targets the 3'-UTR of Csnk1g3 mRNA and promotes its transcription, as demonstrated by dual-luciferase and RNA immunoprecipitation (RIP) assays; Csnk1g3 (CK1γ3) protein participates in the TNF-α/necroptosis (RIP1/RIP3/MLKL) signaling pathway in hippocampal neurons.","method":"Dual-luciferase reporter assay, RNA immunoprecipitation (RIP), qRT-PCR, western blot, flow cytometry, in vivo EEG/histopathology in epileptic mouse model","journal":"Scientific reports","confidence":"Low","confidence_rationale":"Tier 3 / Weak — mechanistic claim about Csnk1g3 in necroptosis pathway is indirect (pathway marker expression changes); the direct mechanistic data concern the circRNA regulating Csnk1g3, not Csnk1g3's own enzymatic mechanism","pmids":["39920301"],"is_preprint":false},{"year":2026,"finding":"circRNA-Csnk1g3 distributes in both nucleus and cytoplasm and directly targets the 3'-UTR of Csnk1g3, promoting its transcription; elevated Csnk1g3 expression is associated with activation of the Wnt/β-catenin pathway and NLRP3 inflammasome-mediated pyroptosis in hippocampal neurons, effects reversed by circRNA-Csnk1g3 knockdown.","method":"FISH (subcellular localization of circRNA), dual-luciferase assay, RIP assay, siRNA knockdown, adenoviral overexpression, western blot, immunofluorescence, qRT-PCR in HT22 cells","journal":"Journal of ethnopharmacology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — pathway placement of Csnk1g3 in Wnt/β-catenin/pyroptosis is correlative; direct enzymatic mechanism of CSNK1G3 protein itself not established; single lab","pmids":["41633109"],"is_preprint":false}],"current_model":"CSNK1G3 (casein kinase I gamma 3) is a kinase that cooperates with the AKT signaling pathway to support cancer cell survival (evidenced by siRNA synthetic lethality with AKT inhibition and modulation of Akt Ser-473/S6 phosphorylation), promotes stop-codon readthrough during translation, and has been placed upstream of Wnt/β-catenin and TNF-α/necroptosis pathways in neuronal cells; its expression is regulated post-transcriptionally by a cognate circRNA that targets its 3'-UTR, but its direct substrates and catalytic mechanism remain uncharacterized in the available literature."},"narrative":{"mechanistic_narrative":"CSNK1G3 (casein kinase I gamma 3) is a kinase implicated in pro-survival signaling in cancer cells, where its knockdown sensitizes cells to Akt inhibition and reduces Akt Ser-473 and ribosomal protein S6 phosphorylation, marking it as an Akt-cooperating kinase required for full Akt pathway activity [PMID:16247451]. Beyond these functional links, its direct substrates and catalytic mechanism have not been characterized in the available corpus. All additional findings carry only Low-confidence support: a role in promoting aminoglycoside-mediated stop-codon readthrough [PMID:29177465], modulation of the AKT/apoptosis/EMT axis in triple-negative breast cancer cells [PMID:39127154], occurrence as an oncogenic CSNK1G3-ALK gene fusion in lung squamous cell carcinoma [PMID:40783309], and placement in TNF-α/necroptosis and Wnt/β-catenin/pyroptosis signaling in hippocampal neurons under post-transcriptional control of a cognate circRNA-Csnk1g3 acting on its 3'-UTR [PMID:39920301, PMID:41633109].","teleology":[{"year":2006,"claim":"Established that CSNK1G3 is functionally required to support Akt pathway activity and cancer cell survival, framing it as a kinase that cooperates with Akt rather than acting independently.","evidence":"Kinome-wide siRNA screen with viability and phosphorylation (Akt Ser-473, S6) readouts under Akt inhibitor A-443654","pmids":["16247451"],"confidence":"Medium","gaps":["No direct substrate of CSNK1G3 identified","Whether CSNK1G3 acts upstream or in parallel to Akt is unresolved","No structural or enzymatic reconstitution of its kinase activity"]},{"year":2018,"claim":"Connected CSNK1G3 to translational fidelity by showing its knockdown reduces stop-codon readthrough, implicating its kinase activity in competition with translation termination.","evidence":"siRNA knockdown in a dual-reporter high-throughput readthrough assay","pmids":["29177465"],"confidence":"Low","gaps":["Single siRNA knockdown assay, single lab, no mechanistic follow-up","No identification of the relevant phosphorylation target in the termination/readthrough machinery"]},{"year":2024,"claim":"Tested CSNK1G3 as a druggable node in the AKT axis by showing a curcumin derivative targeting CSNK1G3 suppresses p-AKT(S473) and modulates apoptosis and EMT in breast cancer cells.","evidence":"Small-molecule (N17) targeting with proliferation, apoptosis, p-AKT and EMT marker assays in triple-negative breast cancer cells","pmids":["39127154"],"confidence":"Low","gaps":["Pharmacological inhibitor study without enzymatic or structural validation; mechanism inferred from inhibitor effect","Specificity of the inhibitor for CSNK1G3 over other kinases not biochemically confirmed"]},{"year":2025,"claim":"Identified CSNK1G3 as a fusion partner driving oncogenesis, showing a CSNK1G3-ALK fusion behaves as an ALK-TKI-responsive oncogenic driver.","evidence":"DNA-based NGS detecting the fusion plus PDX model treated with ALK-TKIs (alectinib, crizotinib, lorlatinib) with tumor shrinkage readout","pmids":["40783309"],"confidence":"Low","gaps":["Single case/PDX model with no biochemical characterization of the fusion protein's kinase activity","Contribution of the CSNK1G3 portion versus ALK kinase domain to oncogenicity unknown"]},{"year":2026,"claim":"Defined post-transcriptional regulation of CSNK1G3 and placed it in neuronal cell-death pathways, showing a cognate circRNA targets its 3'-UTR while elevated CSNK1G3 correlates with necroptosis, Wnt/β-catenin and NLRP3-pyroptosis signaling in hippocampal neurons.","evidence":"FISH, dual-luciferase, RIP, siRNA knockdown, adenoviral overexpression, western blot and IF in HT22 cells and epileptic mouse model","pmids":["39920301","41633109"],"confidence":"Low","gaps":["Pathway placement is correlative via marker expression, not direct enzymatic linkage","Direct substrates of CSNK1G3 in necroptosis/Wnt/pyroptosis pathways not identified","Mechanism by which the circRNA regulates CSNK1G3 transcription versus mRNA stability is not resolved"]},{"year":null,"claim":"The direct substrates, catalytic mechanism, and structural basis of CSNK1G3 kinase activity remain unknown across all documented contexts.","evidence":"No reconstituted enzymatic or structural study present in the corpus","pmids":[],"confidence":"Low","gaps":["No phosphorylation substrate directly demonstrated","No structural model or active-site characterization","Mechanistic basis for its many proposed pathway roles unestablished"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0]}],"localization":[],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0]}],"complexes":[],"partners":[],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9Y6M4","full_name":"Casein kinase I isoform gamma-3","aliases":[],"length_aa":447,"mass_kda":51.4,"function":"Serine/threonine-protein kinase. Casein kinases are operationally defined by their preferential utilization of acidic proteins such as caseins as substrates. It can phosphorylate a large number of proteins. Participates in Wnt signaling. Regulates fast synaptic transmission mediated by glutamate (By similarity)","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q9Y6M4/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CSNK1G3","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000151292","cell_line_id":"CID001165","localizations":[{"compartment":"cytoplasmic","grade":3},{"compartment":"membrane","grade":3}],"interactors":[{"gene":"ABI2","stoichiometry":0.2},{"gene":"ABI1","stoichiometry":0.2},{"gene":"WASF1","stoichiometry":0.2},{"gene":"BAIAP2","stoichiometry":0.2},{"gene":"NCKAP1","stoichiometry":0.2},{"gene":"WASF2","stoichiometry":0.2},{"gene":"BAIAP2L1","stoichiometry":0.2},{"gene":"KIAA1522","stoichiometry":0.2},{"gene":"YWHAG","stoichiometry":0.2},{"gene":"YWHAZ","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID001165","total_profiled":1310},"omim":[{"mim_id":"606274","title":"CASEIN KINASE I, GAMMA-1; CSNK1G1","url":"https://www.omim.org/entry/606274"},{"mim_id":"604253","title":"CASEIN KINASE I, GAMMA-3; CSNK1G3","url":"https://www.omim.org/entry/604253"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CSNK1G3"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"Q9Y6M4","domains":[{"cath_id":"3.30.200.20","chopping":"37-116","consensus_level":"high","plddt":93.4521,"start":37,"end":116},{"cath_id":"1.10.510.10","chopping":"120-314","consensus_level":"high","plddt":96.9565,"start":120,"end":314}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y6M4","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y6M4-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y6M4-F1-predicted_aligned_error_v6.png","plddt_mean":76.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CSNK1G3","jax_strain_url":"https://www.jax.org/strain/search?query=CSNK1G3"},"sequence":{"accession":"Q9Y6M4","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9Y6M4.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9Y6M4/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y6M4"}},"corpus_meta":[{"pmid":"27485317","id":"PMC_27485317","title":"Estimation of genetic parameters and detection of chromosomal regions affecting the major milk proteins and their post translational modifications in Danish Holstein and Danish Jersey cattle.","date":"2016","source":"BMC genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27485317","citation_count":53,"is_preprint":false},{"pmid":"16247451","id":"PMC_16247451","title":"RNAi-based screening of the human kinome identifies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16247451","citation_count":44,"is_preprint":false},{"pmid":"29177465","id":"PMC_29177465","title":"Aminoglycoside-mediated promotion of translation readthrough occurs through a non-stochastic mechanism that competes with translation termination.","date":"2018","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29177465","citation_count":18,"is_preprint":false},{"pmid":"33170928","id":"PMC_33170928","title":"Detecting Genetic Ancestry and Adaptation in the Taiwanese Han People.","date":"2021","source":"Molecular biology and evolution","url":"https://pubmed.ncbi.nlm.nih.gov/33170928","citation_count":14,"is_preprint":false},{"pmid":"33084421","id":"PMC_33084421","title":"Autoimmune response against tyrosinase induces depigmentation in C57BL/6 black mice.","date":"2020","source":"Autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/33084421","citation_count":13,"is_preprint":false},{"pmid":"40706934","id":"PMC_40706934","title":"Differential analysis of testicular LncRNA in Kazakh horses of different ages.","date":"2025","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/40706934","citation_count":8,"is_preprint":false},{"pmid":"28361102","id":"PMC_28361102","title":"Gene-centric analysis implicates nuclear encoded mitochondrial protein gene variants in migraine susceptibility.","date":"2017","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28361102","citation_count":6,"is_preprint":false},{"pmid":"39127154","id":"PMC_39127154","title":"Novel curcumin derivatives N17 exert anti-cancer effects through the CSNK1G3/AKT axis in triple-negative breast cancer.","date":"2024","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39127154","citation_count":3,"is_preprint":false},{"pmid":"40783309","id":"PMC_40783309","title":"Clinical Outcomes of Patients With Advanced ALK-Rearranged Lung Squamous Cell Carcinoma Treated With ALK Tyrosine Kinase Inhibitors.","date":"2025","source":"Clinical lung cancer","url":"https://pubmed.ncbi.nlm.nih.gov/40783309","citation_count":3,"is_preprint":false},{"pmid":"40842671","id":"PMC_40842671","title":"Dietary Influence on Urolithiasis Risk Mediated by Plasma Metabolites: A Mendelian Randomization and Experimental Study Linking Genes, Metabolites, and Clinical Outcomes.","date":"2025","source":"Food science & nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/40842671","citation_count":2,"is_preprint":false},{"pmid":"39920301","id":"PMC_39920301","title":"Mitigating effects of Jiawei Chaihu Shugan decoction on necroptosis and inflammation of hippocampal neurons in epileptic mice.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/39920301","citation_count":1,"is_preprint":false},{"pmid":"41633109","id":"PMC_41633109","title":"Investigating the effect of Dingxian Pill on hippocampal neuronal pyroptosis in epilepsy through regulation of the circRNA-Csnk1g3/Wnt/β-catenin pathway.","date":"2026","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/41633109","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":9030,"output_tokens":1688,"usd":0.026205,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":8498,"output_tokens":2161,"usd":0.048258,"stage2_stop_reason":"end_turn"},"total_usd":0.074463,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2006,\n      \"finding\": \"siRNA knockdown of CSNK1G3 significantly enhanced cancer cell killing in the presence of Akt inhibitor A-443654 and caused decreases in Akt Ser-473 and ribosomal protein S6 phosphorylation, identifying CSNK1G3 as an Akt-cooperating kinase required for Akt pathway activity in cancer cells.\",\n      \"method\": \"siRNA screen (kinome-wide RNAi library) with cell viability and phosphorylation readouts (Akt Ser-473, S6 phosphorylation)\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — functional siRNA knockdown with defined molecular readouts (phosphorylation), single lab, single method\",\n      \"pmids\": [\"16247451\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"siRNA knockdown of CSNK1G3 negatively regulated aminoglycoside-mediated translation readthrough, indicating that CSNK1G3 kinase activity promotes readthrough at stop codons in competition with translation termination.\",\n      \"method\": \"siRNA knockdown in dual reporter-based high-throughput readthrough assay (enzymatic and fluorescence activities)\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single siRNA knockdown assay, single lab, no direct mechanistic follow-up on how CSNK1G3 mediates the effect\",\n      \"pmids\": [\"29177465\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"The curcumin derivative N17 inhibits p-AKT(S473) by specifically targeting CSNK1G3 protein, and CSNK1G3 was shown to regulate the AKT signaling axis controlling apoptosis and epithelial-mesenchymal transition in triple-negative breast cancer cells.\",\n      \"method\": \"Small-molecule targeting of CSNK1G3 with cell proliferation, apoptosis, and phosphorylation assays (p-AKT Ser473); EMT marker analysis\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, pharmacological inhibitor study without direct enzymatic reconstitution or structural validation; mechanism inferred from inhibitor effect\",\n      \"pmids\": [\"39127154\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"A novel CSNK1G3-ALK gene fusion was identified in a lung squamous cell carcinoma patient, functioning as an oncogenic driver responsive to ALK tyrosine kinase inhibitors (alectinib, crizotinib, lorlatinib) in both the patient and a patient-derived xenograft model.\",\n      \"method\": \"DNA-based next-generation sequencing (NGS) identifying fusion; patient-derived xenograft (PDX) model treated with ALK-TKIs with tumor shrinkage readout\",\n      \"journal\": \"Clinical lung cancer\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single case/PDX model, no direct biochemical characterization of the fusion protein's kinase activity or mechanism\",\n      \"pmids\": [\"40783309\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"circRNA-Csnk1g3 directly targets the 3'-UTR of Csnk1g3 mRNA and promotes its transcription, as demonstrated by dual-luciferase and RNA immunoprecipitation (RIP) assays; Csnk1g3 (CK1γ3) protein participates in the TNF-α/necroptosis (RIP1/RIP3/MLKL) signaling pathway in hippocampal neurons.\",\n      \"method\": \"Dual-luciferase reporter assay, RNA immunoprecipitation (RIP), qRT-PCR, western blot, flow cytometry, in vivo EEG/histopathology in epileptic mouse model\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — mechanistic claim about Csnk1g3 in necroptosis pathway is indirect (pathway marker expression changes); the direct mechanistic data concern the circRNA regulating Csnk1g3, not Csnk1g3's own enzymatic mechanism\",\n      \"pmids\": [\"39920301\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"circRNA-Csnk1g3 distributes in both nucleus and cytoplasm and directly targets the 3'-UTR of Csnk1g3, promoting its transcription; elevated Csnk1g3 expression is associated with activation of the Wnt/β-catenin pathway and NLRP3 inflammasome-mediated pyroptosis in hippocampal neurons, effects reversed by circRNA-Csnk1g3 knockdown.\",\n      \"method\": \"FISH (subcellular localization of circRNA), dual-luciferase assay, RIP assay, siRNA knockdown, adenoviral overexpression, western blot, immunofluorescence, qRT-PCR in HT22 cells\",\n      \"journal\": \"Journal of ethnopharmacology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — pathway placement of Csnk1g3 in Wnt/β-catenin/pyroptosis is correlative; direct enzymatic mechanism of CSNK1G3 protein itself not established; single lab\",\n      \"pmids\": [\"41633109\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CSNK1G3 (casein kinase I gamma 3) is a kinase that cooperates with the AKT signaling pathway to support cancer cell survival (evidenced by siRNA synthetic lethality with AKT inhibition and modulation of Akt Ser-473/S6 phosphorylation), promotes stop-codon readthrough during translation, and has been placed upstream of Wnt/β-catenin and TNF-α/necroptosis pathways in neuronal cells; its expression is regulated post-transcriptionally by a cognate circRNA that targets its 3'-UTR, but its direct substrates and catalytic mechanism remain uncharacterized in the available literature.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CSNK1G3 (casein kinase I gamma 3) is a kinase implicated in pro-survival signaling in cancer cells, where its knockdown sensitizes cells to Akt inhibition and reduces Akt Ser-473 and ribosomal protein S6 phosphorylation, marking it as an Akt-cooperating kinase required for full Akt pathway activity [#0]. Beyond these functional links, its direct substrates and catalytic mechanism have not been characterized in the available corpus. All additional findings carry only Low-confidence support: a role in promoting aminoglycoside-mediated stop-codon readthrough [#1], modulation of the AKT/apoptosis/EMT axis in triple-negative breast cancer cells [#2], occurrence as an oncogenic CSNK1G3-ALK gene fusion in lung squamous cell carcinoma [#3], and placement in TNF-\\u03b1/necroptosis and Wnt/\\u03b2-catenin/pyroptosis signaling in hippocampal neurons under post-transcriptional control of a cognate circRNA-Csnk1g3 acting on its 3'-UTR [#4, #5].\",\n  \"teleology\": [\n    {\n      \"year\": 2006,\n      \"claim\": \"Established that CSNK1G3 is functionally required to support Akt pathway activity and cancer cell survival, framing it as a kinase that cooperates with Akt rather than acting independently.\",\n      \"evidence\": \"Kinome-wide siRNA screen with viability and phosphorylation (Akt Ser-473, S6) readouts under Akt inhibitor A-443654\",\n      \"pmids\": [\"16247451\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No direct substrate of CSNK1G3 identified\",\n        \"Whether CSNK1G3 acts upstream or in parallel to Akt is unresolved\",\n        \"No structural or enzymatic reconstitution of its kinase activity\"\n      ]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Connected CSNK1G3 to translational fidelity by showing its knockdown reduces stop-codon readthrough, implicating its kinase activity in competition with translation termination.\",\n      \"evidence\": \"siRNA knockdown in a dual-reporter high-throughput readthrough assay\",\n      \"pmids\": [\"29177465\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"Single siRNA knockdown assay, single lab, no mechanistic follow-up\",\n        \"No identification of the relevant phosphorylation target in the termination/readthrough machinery\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Tested CSNK1G3 as a druggable node in the AKT axis by showing a curcumin derivative targeting CSNK1G3 suppresses p-AKT(S473) and modulates apoptosis and EMT in breast cancer cells.\",\n      \"evidence\": \"Small-molecule (N17) targeting with proliferation, apoptosis, p-AKT and EMT marker assays in triple-negative breast cancer cells\",\n      \"pmids\": [\"39127154\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"Pharmacological inhibitor study without enzymatic or structural validation; mechanism inferred from inhibitor effect\",\n        \"Specificity of the inhibitor for CSNK1G3 over other kinases not biochemically confirmed\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identified CSNK1G3 as a fusion partner driving oncogenesis, showing a CSNK1G3-ALK fusion behaves as an ALK-TKI-responsive oncogenic driver.\",\n      \"evidence\": \"DNA-based NGS detecting the fusion plus PDX model treated with ALK-TKIs (alectinib, crizotinib, lorlatinib) with tumor shrinkage readout\",\n      \"pmids\": [\"40783309\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"Single case/PDX model with no biochemical characterization of the fusion protein's kinase activity\",\n        \"Contribution of the CSNK1G3 portion versus ALK kinase domain to oncogenicity unknown\"\n      ]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Defined post-transcriptional regulation of CSNK1G3 and placed it in neuronal cell-death pathways, showing a cognate circRNA targets its 3'-UTR while elevated CSNK1G3 correlates with necroptosis, Wnt/\\u03b2-catenin and NLRP3-pyroptosis signaling in hippocampal neurons.\",\n      \"evidence\": \"FISH, dual-luciferase, RIP, siRNA knockdown, adenoviral overexpression, western blot and IF in HT22 cells and epileptic mouse model\",\n      \"pmids\": [\"39920301\", \"41633109\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"Pathway placement is correlative via marker expression, not direct enzymatic linkage\",\n        \"Direct substrates of CSNK1G3 in necroptosis/Wnt/pyroptosis pathways not identified\",\n        \"Mechanism by which the circRNA regulates CSNK1G3 transcription versus mRNA stability is not resolved\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The direct substrates, catalytic mechanism, and structural basis of CSNK1G3 kinase activity remain unknown across all documented contexts.\",\n      \"evidence\": \"No reconstituted enzymatic or structural study present in the corpus\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No phosphorylation substrate directly demonstrated\",\n        \"No structural model or active-site characterization\",\n        \"Mechanistic basis for its many proposed pathway roles unestablished\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"complexes\": [],\n    \"partners\": [],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":2,"faith_total":2,"faith_pct":100.0}}